As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Tislelizumab for untreated unresectable hepatocellular carcinoma.
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin in early March 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late May 2024.